Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome

New England Journal of Medicine 2026

View at publisher
Authors: Adrian Gottschlich, Veit Bücklein, Karim El-Marouk, Rainer Kaiser, Michael Schmid, Thomas Alexander Janert, Michael Winkelmann, Frank Ziemann, Gerulf Hänel, Stefan Handtke, T Thiele, Christian Wichmann
+8 more Sebastian Kobold, Gerhard Zugmaier, Christian Rausch, Hendrik Schulze-Koops, Lars H. Lindner, Karsten Spiekermann, Michael von Bergwelt-Baildon, Marion Subklewe
DOI: 10.1056/nejmc2516228
Cited by: 5
References: 4

Abstract

A CD19-targeted therapy induced remission in a woman with refractory immune thrombocytopenia and antiphospholipid syndrome by stabilizing platelet counts, eliminating pathogenic antibodies, and enabling safer long-term anticoagulation.

Fields of Study & Subjects

Platelet Disorders and Treatments Systemic Lupus Erythematosus Research Multiple Myeloma Research and Treatments

Publication details

Journal / source
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Volume
394
Issue
10
Pages
1030–1033
Publication date
4 March 2026
Language
EN